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Abstract
Background: The importance of systemic sclerosis (SSc) autoantibodies for diagnosis has become recognized by
their incorporation into the 2013 ACR/EULAR classification criteria. Clear prognostic and phenotypic associations
with cutaneous subtype and internal organ involvement have been also described. However, little is known about
the potential of autoantibodies to exert a direct pathogenic role in SSc. The aim of the study is to assess the
pathogenic capacity of anti-DNA-topoisomerase I (anti-Topo-I) and anti-centromeric protein B (anti-Cenp-B)
autoantibodies to induce pro-fibrotic markers in dermal fibroblasts.
Methods: Dermal fibroblasts were isolated from unaffected and affected skin samples of (n = 10) limited cutaneous SSc
(LcSSc) patients, from affected skin samples of diffuse cutaneous (DcSSc) patients (n = 10) and from healthy subjects (n = 20).
Fibroblasts were stimulated with anti-Topo-I, anti-Cenp-B IgGs, and control IgGs in ratios 1:100 and 1:200 for 24 h. Cells were
also incubated with 10% SSc anti-Topo-I+ and anti-Cenp-B+ whole serum and with 10% control serum for 24 h. Viability was
assessed by MTT test, while apoptosis was assessed by flow cytometry. Activation of pro-fibrotic genes ACTA2, COL1A1, and
TAGLN was evaluated by quantitative real-time PCR (qPCR), while the respective protein levels alpha-smooth-muscle actin
(α-SMA), type-I-collagen (Col-I), and transgelin (SM22) were assessed by immunocytochemistry (ICC).
Results: MTT showed that anti-Cenp-B/anti-Topo-I IgGs and anti-Cenp-B+/anti-Topo-I+ sera reduced viability (in a dilution-
dependent manner for IgGs) for all the fibroblast populations. Apoptosis is induced in unaffected LcSSc and control
fibroblasts, while affected LcSSc/DcSSc fibroblasts showed apoptosis resistance. Basal mRNA (ACTA2, COL1A1, and TAGLN)
and protein (α-SMA, Col-1, and SM22) levels were higher in affected LcSSc/DcSSc fibroblasts compared to LcSSc unaffected
and to control ones. Stimulation with anti-Cenp-B/anti-Topo-I IgGs and with anti-Cenp-B+/anti-Topo-I+ sera showed a better
induction in unaffected LcSSc and control fibroblasts. However, a statistically significant increase of all pro-fibrotic markers is
reported also in affected LcSSc/DcSSc fibroblasts upon stimulation with both IgGs and sera.
Conclusions: This study suggests a pathogenic role of SSc-specific autoantibodies to directly induce pro-fibrotic activation in
human dermal fibroblasts. Therefore, besides the diagnostic and prognostic use of those autoantibodies, these data might
further justify the importance of immunosuppressive drugs in the early stages of the autoimmune disease, including SSc.
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Background
Systemic sclerosis (scleroderma, SSc) is a rare and het-
erogeneous autoimmune disease characterized by pro-
gressive fibrosis of the skin and internal organs such as
lungs, heart, kidneys, and gastrointestinal tract, coupled
to widespread vascular alterations [1]. The main abnor-
malities of SSc are related to the connective tissue, in
which the excessive production of collagen and other
extracellular matrix components are responsible for a
progressive and, so far irreversible, fibrosis [2]. The clin-
ical phenotype of SSc varies between two main distinct
subsets according to the extent of the skin involvement
[3]: limited cutaneous systemic sclerosis (LcSSc) in
which skin thickening is mainly restricted to the face,
fingers, and forearms [4] and diffuse cutaneous systemic
sclerosis (DcSSc) in which skin lesions are observed on
the trunk and over the elbow and/or knee [5]. It is well
known that SSc has an autoimmune etiology: anti-
nuclear antibodies (ANAs) are detected in more than
95% of patients [6] and the presence of several poten-
tially pathogenic auto-antibodies targeting various ex-
tractable nuclear antigens (ENAs) or other auto-antigens
is also reported [7]. ANAs in SSc are divided into two
categories: SSc-specific ANAs and SSc-associated ANAs
[8]. SSc-specific ANAs are detected in SSc patients and
rarely found in other connective tissue diseases or in
healthy subjects [9]. They include anti-centromere
(ACAs) and anti-DNA topoisomerase I (Topo-I) anti-
bodies mainly, but also anti-RNA polymerase III
(RNAP), anti-U3 ribonucleoprotein (RNP), anti-Th/To,
anti-U11/U12 RNP, anti-eukaryotic initiation factor 2B
(eIF2B), anti-U1 RNP, anti-PM-Scl, anti-Ku, and anti-
RuvBL1/2 antibodies for the minor component. On the
other hand, SSc-associated ANAs are not specific to SSc
but they can occasionally coexist with other connective
tissue disease-related antibodies [10, 11]. The two main
subsets of SSc (LcSSc and DcSSc) do not reflect only a
clinical classification [3], but they are usually associated
with a precise autoimmune pattern: in fact, ACAs and in
particular anti-centromere B (anti-Cenp-B) antibodies
are predominantly associated with LcSSc, while anti-
Topo-I with DcSSc [12]. In fact, while the other SSc-
specific or SSc-associated antibodies can be found in
both LcSSc and DcSSc, it is less frequent to find LcSSc
patients with anti-Topo-I antibodies and DcSSc patients
with anti-Cenp-B antibodies [13]. The utility of SSc-
specific antibodies for both diagnostic and prognostic
purposes has been fully elucidated [14]. In fact, the
ACR/EULAR 2013 classification criteria now include the
presence of ACAs, anti-Topo-I, and anti-RNAP-III anti-
bodies as one of the items to overcome the disadvan-
tages of the 1980 ACR preliminary classification criteria
[15, 16]. Regarding the prognostic utility, the faster pro-
gression of the disease in SSc-specific antibody-positive
patients versus SSc-specific antibody-negative ones has
been demonstrated [17]. ANA-negative SSc patients
(5%) represent one unique subgroup mainly character-
ized by male subjects with less vasculopathy, such as
digital ulcers and pulmonary arterial hypertension
(PAH), and with lower gastrointestinal involvement [18].
Whether ANA-negative SSc patients have other non-
nuclear circulating antibodies has not been currently
elucidated [19]. Taken into account the abovementioned
diagnostic and prognostic utilities of SSc-specific anti-
bodies, the goal of the present study is to investigate
whether those antibodies could have a direct pathogenic
effect on in vitro cultured human fibroblasts.
Materials and methods
Patients and cell cultures
Ten patients with LcSSc and ten patients with DcSSc
who fulfilled the 2013 ACR/EULAR classification criteria
for SSc [15, 16], and ten age- and sex-matched voluntary
healthy subjects were recruited from the Internal Medi-
cine and Rheumatology Units of the University Hospital
of Siena in accordance with the Declaration of Helsinki,
after obtaining signed informed consent and following
the local Ethical Board Committee approval. Clinical and
demographical characteristics of SSc patients are re-
ported in Table 1. Blood was collected from SSc patients
and from healthy subjects, and serum samples were
checked for the presence of autoantibodies according to
normal diagnostic procedures. Skin biopsies were per-
formed using a 3-mm punch on the affected mid-
forearm of patients with LcSSc/DcSSc. Unaffected areas
of skin from the same LcSSc patients and control skin
(site-matched) from gender- and age-matched healthy
subjects were also evaluated. The LcSSc patients’ un-
affected skin was defined by clinical palpation and
graded as zero on the modified Rodnan skin score [20].
Fibroblasts were isolated from skin specimens by enzym-
atic digestion. Briefly, explants were de-epidermized
using a dispase solution (dispase activity 14 U/mL)
(Sigma-Aldrich, St. Louis, MO, USA) for 2 h at 37 °C
and then were dissolved into a type IV collagenase solu-
tion (2.4 U/mL) (Sigma-Aldrich) for 3 h.
The obtained cell suspension was filtered twice using
70-μm nylon meshes, washed, and centrifuged for 5 min
at 700×g. The viability was assessed by Trypan Blue
(Sigma-Aldrich) test identifying 90 to 95% cell survival.
Fibroblasts were recovered, seeded into 10-cm diameter
tissue culture plates, and were expanded twice and cul-
tured in a monolayer incubator with 5% CO2 and 90%
humidified atmosphere at 37 °C until confluence. Cells
were grown in Dulbecco’s modified Eagle medium
(DMEM) (Euroclone, Milan, Italy), containing 10% fetal
bovine serum (FBS) (Euroclone), with 200 U/mL penicil-
lin and 200 μg/mL streptomycin (Sigma-Aldrich) and 2
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mM glutamine (Sigma-Aldrich). The medium was chan-
ged every 3–4 days. The fibroblast morphology was ex-
amined daily with an inverted microscope (Olympus
IMT-2, Tokyo, Japan) to guarantee their phenotypic sta-
bility preserved. For each single experiment, a cell cul-
ture from a unique donor was used.
Fibroblast treatment
Fibroblasts at the third passage were employed for the
experiments. Twelve hours before the experiments, cells
were harvested in a serum-free medium and cultured in
75 cm2 flasks (Euroclone, Milan, Italy).
Human polyclonal anti-centromere B (anti-Cenp-B)
and anti-DNA topoisomerase I (anti-Topo-I) (Abcam,
Cambridge, UK) were first dissolved in phosphate-
buffered saline (PBS) (Euroclone), according to the
manufacturer’s instructions, and then they were di-
luted in the culture medium immediately before the
treatment to reach the final dilution required (1:100
and 1:200). The cells were treated with the condi-
tioned media containing the selected dilutions of anti-
Cenp-B and anti-Topo I and 10% SSc anti-Topo-I+,
anti-Cenp-B+ serum for 24 h. The final concentrations
were chosen based on the best results obtained in
terms of viability (data not shown). To evaluate the
effect of antibodies directed against nuclear proteins
which are not involved in SSc pathophysiology, a human
anti-histone H3 antibody (Abcam) was also tested in par-
allel in control fibroblasts only (Additional file 1).
After the treatment, the media were removed, centri-
fuged, and stored at − 80 °C; the fibroblasts were imme-
diately processed to carry out cell viability assay, flow
cytometry analysis, quantitative real-time PCR, and im-
munofluorescence analysis.
MTT assay
The viability of the cells was evaluated immediately after
the treatment by MTT assay. Fibroblasts from LcSSc/
DcSSc patients and healthy subjects were seeded in 12-
well plates (8 × 104 cells/well) for 24 h in DMEM with
10% FBS. Then, the medium was removed, and the cells
were cultured in DMEM with 0.5% FBS usually used
during the treatment procedure. After that, the cells
were incubated for 3 h at 37 °C in a culture medium
containing 10% of 5 mg/mL MTT (3-[4,4-dimethyl-
thiazol-2-yl]-2,5-diphenyl-tetrazoliumbromide) (Sigma-
Aldrich). After the period of incubation, the medium
was removed and 0.2 mL of dimethyl sulfoxide (DMSO)
Table 1 Demographic and clinical characteristics of patients at the time of biopsy collection
Patients Subset Age (years) Gender (M/F) Disease duration
(years)
Autoantibody mRSS Organ involvement Therapy
1 LcSSc 57 F 12 Anti-Cenp-B 17 Lung (ILD), digital ulcers ERAs, prednisone
2 LcSSc 62 F 5 Anti-Cenp-B 4 Esophagus Ca2+ antagonists, PPIs
3 LcSSc 70 M 9 Anti-Cenp-B 14 Lung (ILD), esophagus ERAs, PPIs, MMF
4 LcSSc 67 F 10 Anti-Cenp-B 5 Esophagus Ca2+ antagonists, PPIs
5 LcSSc 48 F 8 Anti-Cenp-B 14 Lung (ILD) ERAs, Prednisone, MMF
6 LcSSc 55 F 11 Anti-Cenp-B 7 Lung (ILD) ERAs, Prednisone
7 LcSSc 58 F 13 Anti-Cenp-B 17 Lung (ILD), esophagus ERAs, PPIs, MMF
8 LcSSc 44 F 2 Anti-Cenp-B 7 Lung (PAH), esophagus Ca2+ antagonists, PPIs, prostanoids
9 LcSSc 66 F 7 Anti-Cenp-B 14 Digital ulcers
esophagus
ERAs, PPIs
10 LcSSc 60 F 9 Anti-Cenp-B 5 Esophagus Ca2+ antagonists, PPIs
11 DcSSc 51 F 12 Anti-Topo-I 7 Lung (PAH), digital ulcers Ca2+ antagonists, ERAs, prostanoids
12 DcSSc 72 M 11 Anti-Topo-I 17 Lung (PAH), digital ulcers ERAs, prostanoids, MMF
13 DcSSc 64 F 7 Anti-Topo-I 17 Lung (PAH), digital ulcers ERAs, prostanoids, MMF
14 DcSSc 63 M 13 Anti-Topo-I 12 Lung (ILD) ERAs, prednisone, MMF
15 DcSSc 50 F 6 Anti-Topo-I 9 Lung (ILD), esophagus Ca2+ antagonists, PPIs
16 DcSSc 68 F 15 Anti-Topo-I 14 Lung (ILD) ERAs, prednisone, MMF
17 DcSSc 59 F 14 Anti-Topo-I 17 Esophagus Ca2+ antagonists, PPIs
18 DcSSc 69 M 7 Anti-Topo-I 17 Lung (PAH) ERAs, prostanoids
19 DcSSc 49 F 9 Anti-Topo-I 14 Lung (PAH), esophagus ERAs, prostanoids, PPIs
20 DcSSc 61 F 11 Anti-Topo-I 17 Lung (ILD), esophagus Ca2+ antagonists, PPIs, MMF
Abbreviations: Cenp-B centromeric protein B, ERAs endothelin receptor antagonists, ILD interstitial lung disease, MMF mycophenolate mofetil, mRSS modified
Rodnan skin score, PPIs proton pump inhibitors, PAH pulmonary arterial hypertension, Topo-I topoisomerase I
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(Rottapharm Biotech, Monza, Italy) was added to each
well to solubilize the formazan crystals. The absorbance
was measured at 570 nm in a microplate reader (BioTek
Instruments, Inc., Winooski, VT, USA). A control well
without cells was employed for blank measurement. The
percentage of survival cells was evaluated as follows: %
of survival cells = (absorbance of considered sample) /
(absorbance of control) × 100. The experiments were
performed on sub-confluent cell cultures in order to
prevent contact inhibition which can condition the re-
sults. Data were normalized and reported as optical
density (OD) units per 104 adherent cells.
Detection of apoptosis
The evaluation of apoptotic cells was developed by
using Annexin V-FITC and propidium iodide (PI)
(Thermo Fisher Scientific, Milan, Italy). Fibroblasts
from LcSSc/DcSSc patients and healthy subjects were
seeded in 12-well plates (8 × 104 cells/well) for 24 h in
DMEM with 10% FBS. Then, the medium was re-
moved, and the cells were cultured in DMEM with
0.5% FBS usually used during the treatment procedure
described before. After that, the fibroblasts were
washed and harvested by using trypsin, collected into
cytometry tubes, and centrifuged at 1500 rpm for 10
min. The supernatant was replaced, and the pellet
was resuspended in 100 μL of 1× Annexin-binding
buffer, 5 μL of Alexa Fluor 488 annexin-V conjugated
to fluorescein (green fluorescence), and 1 μL of
100 μg/mL PI working solution. Cells were incubated
at room temperature for 15 min in the dark. Then,
600 μL of 1× Annexin-binding buffer was added be-
fore the analysis at flow cytometer. A total of 10,000
events (1 × 104 cells per assay) were measured by the
instrument. The obtained results were analyzed with
Cell Quest software (Version 4.0, Becton Dickinson,
San Jose, CA, USA). The evaluation of apoptosis was
carried out considering staining cells simultaneously
with Alexa Fluor 488 annexin-V and PI; this allowed
to discriminate intact cells (annexin-V and PI-
negative), early apoptosis (annexin-V-positive and PI-
negative), and late apoptosis (annexin-V and PI posi-
tives) [21]. The results were normalized per 104 cells
and expressed as a ratio of positive cells to each dye
(total apoptosis), and the data were represented as
the mean of three independent experiments (mean ±
standard deviation (SD)). To determine the impact of
apoptosis on fibroblast pro-fibrotic activation, inhibi-
tor of apoptosis (IAP) AZD 5582 dihydrochloride
(Sigma-Aldrich) compound was added to control fi-
broblasts 2 h before the stimulation with anti-Cenp-B
(1:100) and anti-Topo-I (1:100) IgGs. The final con-
centration chosen is 50 nM after appropriate dose
finding (Additional file 1).
RNA isolation and quantitative real-time PCR
Fibroblasts from LcSSc/DcSSc patients and healthy sub-
jects were seeded in 6-well dishes at a starting density of
6 × 106 cells/well for 24 h in DMEM with 10% FBS.
Then, the medium was removed, and the cells were cul-
tured in DMEM with 0.5% FBS usually used during the
treatment procedure.
Total RNA was extracted using TriPure Isolation
Reagent (Euroclone) according to the manufacturer’s in-
structions and was stored at − 80 °C. The concentration,
purity, and integrity of RNA were evaluated by measur-
ing the OD at 260 nm and the 260/280 and 260/230 ra-
tios by Nanodrop-1000 (Celbio, Milan, Italy). The
quality of RNA was verified by electrophoresis on agar-
ose gel (Flash Gel System, Lonza, Rockland, ME, USA).
Reverse transcription for target genes was carried by
QuantiTect Reverse Transcription Kit (Qiagen, Hilden,
Germany), according to the manufacturer’s instructions.
Then, target genes were examined by real-time PCR
by using QuantiFast SYBR Green PCR (Qiagen) kit. A
list of the used primers is reported in Table 2. All qPCR
reactions were achieved in glass capillaries by a LightCy-
cler 1.0 (Roche Molecular Biochemicals, Mannheim,
Germany) with LightCycler Software Version 3.5. The
reaction procedure for target gene amplification was
performed at 5 in at 95 °C, 40 cycles of 15 s at 95 °C, and
30 s at 60 °C. In the final step of the protocol, the
temperature was raised from 60 to 95 °C at 0.1 °C/step
to plot the melting curve.
To further analyze the dissociation curves, we visual-
ized the amplicon lengths in an agarose gel to confirm
the correct amplification of the resulting PCR products.
For the data analysis, the Ct values of each sample and
the efficiency of the primer set were calculated through
LinReg Software [22] and then converted into relative
quantities and normalized using the Pfaffl model [23].
The normalization was performed considering human
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as
the housekeeping gene. This gene was chosen according
to geNorm software version 3.5 [24].
Immunofluorescence
Fibroblasts derived from LcSSc/DcSSc patients and
from healthy subjects were plated in coverslips in
Petri dishes (35 × 10 mm) at a starting low density of
4 × 104 cells/chamber, to prevent possible cell overlap-
ping, and re-suspended in 2 mL of culture medium
until 80% of confluence. The cells were processed after 24
h of treatment to evaluate the cytoplasmic localization of
α-SMA, Col-I, and SM22. The fibroblasts were washed in
PBS (Euroclone) and then fixed in 4% paraformaldehyde
solution (Sigma-Aldrich) for 15min at room temperature.
Afterwards, to permeabilize cell membranes, cells were in-
cubated in Triton-X 100 0.2% solution for 30min at room
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temperature. Fibroblasts were washed twice in PBS and
incubated at 4 °C overnight with anti-human α-SMA
(Abcam) diluted at 1:100 in PBS and Triton-X 100 0.05%
solution, anti-human type I collagen (Abcam) diluted at 1:
100 in PBS and Triton-X 100 0.05% solution and with
anti-human SM22 (Abcam) diluted at 1:100 in PBS and
Triton-X 100 0.05% solution. Three washes in PBS of the
coverslips were followed by 1 h incubation with goat anti-
mouse IgG-Texas Red-conjugated antibody (Southern
Biotechnology, Italy) diluted at 1:100 in PBS and Triton-X
100 0.05% solution. Cells were then washed twice in PBS
and incubated for 10min with DAPI solution (diluted 1:
10000) (Abcam). Finally, the coverslips were mounted
with Vecta shield (Vector Labs). Fluorescence was exam-
ined under an AxioPlan (Zeiss, Oberkochen, Germany)
light microscope equipped with epifluorescence at × 200
and × 400 magnification. The negative controls were ob-
tained by omitting the primary antibody. Immunoreactiv-
ity of α-SMA, Col-1, and SM22 were semi-quantified as
the mean densitometric area of α-SMA and Col-I signal
into the cytoplasm, by AxioVision 4.6 software measure
program [25]. At least 100 fibroblasts from each group
were evaluated.
Statistical analysis
Three independent experiments were carried out, and
the results were expressed as the mean ± SD of triplicate
values for each experiment. Data normal distribution
was evaluated by Shapiro–Wilk, D’Agostino and Pear-
son, and Kolmogorov–Smirnov tests. Data from real-
time PCR were evaluated by one-way ANOVA with a
Tukey’s post hoc test using 2−ΔΔCT values for each sam-
ple [26]. All analyses were performed through the SAS
System (SAS Institute Inc., Cary, NC, USA) and Graph-
Pad Prism 6.1. A significant value was defined with a p
value < 0.05.
Results
Cell viability and apoptosis
Results for viability and apoptosis are reported in Fig. 1.
At basal levels, the viability of affected LcSSc and DcSSc
fibroblasts resulted decreased compared to control ones.
LcSSc-unaffected fibroblasts resulted also a bit less vi-
able than control ones, but not at the levels of LcSSc/
DcSSc-affected ones. Anti-Cenp-B and with more extent
anti-Topo-I IgGs reduced mainly unaffected LcSSc and
control fibroblast (and with less extent affected LcSSc/
DcSSc ones) viability in a dilution-dependent manner
compared to control IgGs. Similar results were obtained
with anti-Cenp B+ and anti-Topo-I+ sera compared to
control sera and to SSc sera negative for anti-Cenp-B,
anti-Topo-I antibodies and for other ENAs. Flow cytom-
etry analysis revealed that both anti-Cenp-B/anti-Topo-I
IgGs and anti-Cenp B+/anti-Topo-I+ sera induce apop-
tosis in unaffected LcSSc and control fibroblasts only,
while affected LcSSc and DcSSc fibroblasts showed
apoptosis resistance. Anti-histone H3 antibody treat-
ment did not influence viability and apoptosis (Add-
itional file 1). Regarding the IAP, AZD 5582
dihydrochloride showed its efficacy in inhibiting apop-
tosis and increase viability in control fibroblasts upon
stimulation with anti-Cenp-B, anti-Topo-I, and anti-
Histone H3 IgGs (Additional file 1).
Gene expression
Gene expression levels are reported in Fig. 2. At basal
levels, ACTA2, COL1A1, and TAGLN are statistically
higher in affected LcSSc and DcSSc fibroblasts com-
pared to control ones. Stimulation with anti-Cenp-B and
anti-Topo-I IgGs statistically increased all the profibrotic
markers compared to control IgGs. Control and un-
affected LcSSc fibroblasts seem to be more prone to IgG
stimulation than affected LcSSc/DcSSc ones. Stimulation
with anti-Cenp-B+ and anti-Topo-I+ sera increased
ACTA2, COL1A1, and TAGLN expressions compared
to control sera and to SSc Cenp-B−/Topo-I− sera for all
the fibroblast populations. Finally, inhibition of apoptosis
did not change the mRNA upregulation of all the pro-
fibrotic markers upon stimulation with anti-Cenp-B,
anti-Topo-I, and anti-Histone H3 IgGs in control fibro-
blasts (Additional file 1).
Immunofluorescence
Results for immunofluorescence are shown in Fig. 3. At
basal levels (before the treatment), α-SMA, Col-I, and
SM22 are statistically higher in affected LcSSc and
DcSSc fibroblasts compared to control ones. Stimulation
with anti-Cenp-B and anti-Topo-I IgGs and with anti-
Table 2 Primers used for RT-qPCR
Cat. no. (Qiagen) Forward sequence Reverse sequence
Target gene
ACTA2 QT00088102 CTATGCCTCTGGACGCACAACT CAGATCCAGACGCATGATGGCA
COL1A1 QT00037793 GATTCCCTGGACCTAAAGGTGC AGCCTCTCCATCTTTGCCAGCA
TAGLN QT00072247 TCCAGGTCTGGCTGAAGAATGG CTGCTCCATCTGCTTGAAGACC
Housekeeping gene
GAPDH QT00079247 GTCTCCTCTGACTTCAACAGCG ACCACCCTGTTGCTGTAGCCAA
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Cenp-B+ and anti-Topo-I+ sera statistically increased all
the profibrotic markers compared to control IgGs, to
control sera and to SSc sera negative for anti-Cenp-B
and anti-Topo-I antibodies and for other ENAs. In Fig. 4,
representative images of ICC assay for all the three
markers (α-SMA, Col-I, and SM22) confirm consistency
with the ICC quantification data. Same as for qPCR, in-
hibition of apoptosis did not change the protein upregu-
lation of all the pro-fibrotic markers upon stimulation
with anti-Cenp-B, anti-Topo-I, and anti-Histone H3
IgGs in control fibroblasts (Additional file 1).
Discussion
To the best of our knowledge, this is the first study in
which the direct effect of antibodies targeting SSc-
specific ENAs that are anti-Cenp-B and anti-Topo-I has
been evaluated on the pro-fibrotic activation of cultured
human dermal fibroblasts and their subsequent differen-
tiation into a myofibroblast phenotype in vitro. SSc-
specific antibodies have been used mainly as indicators
of clinical subsets of the disease [27]. Moreover, these
antibodies are as important tools for the prediction of
possible organ involvement [28]. However, very little is
known about their direct pathogenic effect on different
cell phenotypes in the disease [29]. What is known in
the population of SSc antibody patients is that patients
with anti-Cenp-B antibodies (usually LcSSc patients)
more frequently develop pulmonary arterial hyperten-
sion (PAH) and prolonged gastrointestinal transit time
[30], while SSc patients with anti-Topo-I antibodies
(usually DcSSc patients) are linked with a higher prob-
ability of interstitial lung disease (ILD), renal vascular
damage, renal crisis, and heart fibrosis [31]. All these in-
ternal organ complications involve the fibroblast as the
key effector cell phenotype driving the fibrotic process
in SSc [32]: therefore, there must be a direct and/or in-
direct link between the presence of anti-Cenp-B/anti-
Topo-I antibodies and the pro-fibrotic activation of fi-
broblasts. In literature, there are some hypotheses on
how those antibodies could indirectly mediate the fi-
brotic development in SSc [33, 34]. Among these, the
hypothesis that SSc-specific antibodies could trigger the
fibrotic development by inducing microvascular alter-
ations and subsequent tissue remodeling is one of the
most reliable [35]. Another important hypothesis is that
SSc-specific antibodies form immune complexes (ICs)
upon their interaction with soluble target antigens [36]:
it has been demonstrated that ICs containing anti-Cenp-
B/anti-Topo-I antibodies induce a pro-fibrotic and pro-
inflammatory phenotype in dermal fibroblasts [37]. Par-
ticularly, scientists demonstrated that Topo-I binding to
fibroblast surfaces is both necessary and sufficient for
anti-Topo-I binding [38]. Second, Topo-I/anti-Topo-I
complex binding can then trigger the adhesion and acti-
vation of monocytes, thus providing a plausible model
for the amplification of the fibrogenic cascade in anti-
Topo-I-positive SSc patients [39]. To some extent, this
model looks very artificial since Topo-I should be an
Fig. 1 Viability (top row) and apoptosis (bottom row) detected in control, unaffected LcSSc, affected LcSSc, and affected DcSSc fibroblasts at
basal levels (untreated) and after stimulation with anti-Cenp-B (ratios 1:100 and 1:200)/anti-Topo-I (ratios 1:100 and 1:200) antibodies and with SSc
sera (10% v/v in DMEM). Data were normalized per 104 cells. The statistics is reported with respect to the “Control.” “Control” for IgG stimulations
is referred to human healthy control IgGs in a ratio 1:100 in culture medium (DMEM). “Control” for serum stimulation is referred to as human
healthy control serum at 10% v/v in DMEM. (*p < 0.05, **p < 0.01). For SSc serum treatments, Cenp-B-/Topo-I treatment refers to SSc serum
negative for all ENAs
Corallo et al. Arthritis Research & Therapy          (2019) 21:152 Page 6 of 11
intracellular antigen (it is usually located in the nucleus)
and not an extracellular one [40]. However, subsequent
in vivo studies demonstrated that Topo-I released from
injured endothelial cells could bind to bystander fibro-
blasts thus displaying chemoattractant activity toward
immature dendritic cells and human monocytes [41].
These results represent a clear demonstration that
Topo-I could display an extracellular role that can affect
fibroblast physiology. Similar results were found for
Cenp-B antigen [42]: in particular, scientists demon-
strated that Cenp-B released from apoptotic endothelial
cells in vivo binds more specifically to the surface of hu-
man pulmonary artery smooth muscle cells (SMCs) than
fibroblasts [43]; in particular, Cenp-B binds preferentially
to SMCs of the contractile type rather than to SMCs of
the synthetic type [44]. The different Cenp-B selectivity
of binding to SMCs rather than to fibroblasts could ex-
plain our results showing that anti-Topo-I antibodies
have a stronger effect on fibroblasts than anti-Cenp-B
ones. The different target cells of Cenp-B (SMCs) and
Topo-I (fibroblasts) autoantigens released by apoptotic
endothelial cells could also partially explain the different
complications and organ involvement between LcSSc
and DcSSc [45]. Both Cenp-B and Topo-I models as-
sume an already established endothelial damage as a
source of autoantigens binding to targeting cells and
generating a specific pathogenic autoantibody (anti-
Cenp-B and anti-Topo-I) response. However, these
models are quite in disagreement with the timing of the
disease evolution since those specific circulating auto-
antibodies could be detected in SSc patients before an
established endothelial damage [46]. This is also the rea-
son why in the past the use of Topo-I inhibitors for the
treatment of SSc patients resulted unsuccessful [47].
With the results of the present study, we assume that
anti-Cenp-B and anti-Topo-I antibodies could exert a
direct pathogenic role, and therefore, they could be con-
sidered “functional antibodies.” In fact, an autoantibody
is considered “functional” if its direct interaction with an
identified target antigen leads to a molecular pathway
activation or inhibition that can be replicated in an ex-
perimental setting [48]. Therefore, the results of the
present study suggest a new interpretation of the role of
anti-Cenp-B and anti-Topo-I antibodies in the disease in
Fig. 2 qPCR results for ACTA2 (top row), COL1A1 (middle row), and TAGLN (bottom row) in control, unaffected LcSSc, affected LcSSc, and
affected DcSSc fibroblasts at basal levels (untreated) and after stimulation with anti-Cenp-B (ratios 1:100 and 1:200)/anti-Topo-I (ratios 1:100 and
1:200) antibodies and with SSc sera (10% v/v in DMEM). The statistics is reported with respect to the “Control.” “Control” for IgG stimulations is
referred to human healthy control IgGs in a ratio 1:100 in culture medium (DMEM). “Control” for serum stimulation is referred to as human
healthy control serum at 10% v/v in DMEM. Data are reported as fold change vs “Control” (*p < 0.05, **p < 0.01, ***p < 0.001)
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Fig. 3 ICC results for α-SMA (top row), Col-1 (middle row), and SM22 (bottom row) in control, unaffected LcSSc, affected LcSSc and affected
DcSSc fibroblasts at basal levels (untreated) and after stimulation with anti-Cenp-B (ratios 1:100 and 1:200)/anti-Topo-I (ratios 1:100 and 1:200)
antibodies and with SSc sera (10% v/v in DMEM). The statistics is reported with respect to the “Control.” “Control” for IgG stimulations is referred
to human healthy control IgGs in a ratio 1:100 in culture medium (DMEM). “Control” for serum stimulation is referred to as human healthy control
serum at 10% v/v in DMEM. Data are reported as Immunolabeling Intensity vs “Control”. Immunolabeling Intensity corresponds to the formula
I × A/n where I = intensity levels, A = area, n = number of cells (*p < 0.05, **p < 0.01, ***p < 0.001)
Fig. 4 ICC representative images for all the three profibrotic markers α-SMA (top row), Col-1 (middle row), and SM22 (bottom row) in control
fibroblasts stimulated with IgGs (a) and with sera (b). For IgG stimulation (a), data are represented for ratio 1:100 only due to the better window
shown in qPCR and ICC quantification. For serum stimulation (b), data are represented with respect to SSc sera negative for anti-Cenp-B and anti-
Topo-I antibodies and for other ENAs. Negative control is represented in the middle and obtained by replacing the primary antibody with PBS
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terms of disease drivers and not only representing an
epiphenomenon and/or useful diagnostic and prognostic
tools. In fact, we believe that these main autoantibodies,
when present in the circulation even years before the
clinical involvement, need to be tackled to slow down or
prevent disease development. To prove this hypothesis,
we have support from literature: it has been demon-
strated that ubiquitous nuclear protein Cenp-B is the
main target of anti-endothelial cell antibodies (AECA) in
patients with LcSSc and that AECA from DcSSc patients
bind to endothelial cell topoisomerase I, suggesting that
classical autoantibodies such as anti-Cenp-B and anti-
Topo-I antibodies could act as AECA inducing cell-
mediated toxicity and apoptosis in the early stages of the
disease [49]. In this scenario, the use of immunosuppres-
sive drugs and/or the development of more specific
drugs targeting anti-Cenp-B and anti-Topo-I antibodies
should be recommended at an early stage of the disease
to prevent future organ damage or decrease the fibrotic
evolution. In this regard, we underline that in the litera-
ture, to our knowledge, there are no studies on the pro-
gress and the possible decrease of the autoantibody titer
during immunosuppressive therapy. Another important
finding evidenced in this work is the different respon-
siveness of the fibroblasts to those autoantibodies ac-
cording to their differentiation stage: healthy and
unaffected LcSSc fibroblasts were more prone to be acti-
vated upon stimulation with anti-Cenp-B and anti-
Topo-I antibodies than affected LcSSc and DcSSc fibro-
blasts that resulted already differentiated into activated
myofibroblasts, thus secreting the maximum level of
pro-fibrotic proteins. On the other hand, healthy and
unaffected LcSSc fibroblasts were also more susceptible
to apoptosis than affected LcSSc and DcSSc ones, sug-
gesting that the fate of fibroblasts depends not only on
autoantibodies but on a combination of specific auto-
antibodies (e.g., anti-histone antibodies did not induce
apoptosis) and other soluble factors: in fact what we call
healthy or unaffected LcSSc fibroblasts are cells that,
upon stimulation with autoantibodies, they secrete a
maximum amount of pro-fibrotic proteins and then
undergo apoptosis. On the other hand, what we call af-
fected LcSSc and DcSSc fibroblasts are cells that already
express high amount of pro-fibrotic proteins and, upon
stimulation with autoantibodies, they keep producing
collagen and other contractile proteins but with apop-
tosis resistance, so the self-sustained pro-fibrotic loop is
established [50]. This theory is in line with recently pub-
lished literature in which it has been demonstrated that
mitochondria in activated myofibroblasts, but not quies-
cent fibroblasts, are primed by death signals (proximity
to the apoptotic threshold) which creates a requirement
for tonic expression of the antiapoptotic proteins to en-
sure myofibroblast survival [51]. In this irreversible loop,
the inefficient removal of nuclear components of cells
targeted by the autoantibodies (defective cellular “waste
disposal” theory) may also lead to the release and pro-
longed exposure of nuclear components and thus to the
generation of new autoantibodies with increased or
stable titers in sera of SSc patients.
Conclusions
In conclusion, we suggest to re-consider the use of SSc-
specific antibodies not only as useful diagnostic and
prognostic tools, but also as therapeutic targets of the
disease itself. We acknowledge that our study presents
intrinsic limitations. Being an in vitro study, it might be
oversimplified, not allowing an adequate reproduction of
the complexity of the disease pathogenesis. Moreover,
the direct pathogenic role of other SSc-related autoanti-
bodies (e.g., anti-RNA polymerase III) needs to be fur-
ther investigated.
Additional file
Additional file 1: Viability and apoptosis (left panel) and qPCR and ICC
(right panel) data regarding control fibroblasts stimulated with specific
SSc-autoantibodies (anti-Cenp-B, anti-Topo-I IgGs 1:100) and with SSc-
unrelated one (anti-Histone H3 IgGs 1:100) with and without the pre-
incubation (2 h) with an anti-apoptotic compound (IAP, AZD 5582
dihydrochloride, 50 nM) (*p < 0.05). (TIF 42160 kb)
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